Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults with Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (alone or with Pioglitazone and/or SGLT2 inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period

Next Previous
X
Search
Trial Profile

A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults with Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (alone or with Pioglitazone and/or SGLT2 inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Albiglutide; Dulaglutide; Exenatide; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms LixiLan-G
  • Sponsors Sanofi

    • Most Recent Events

    • 22 Feb 2024 Results of pooled analysis of four studies (LixiLan-O, LixiLan-G, LixiLan-L, SoliMix) assessing efficacy and safety of iGlarLixi in older people (≥65 years) with type 2 diabetes (T2D) advancing or switching from oral agents, published in the Diabetes, Obesity and Metabolism.
    • 26 Jun 2023 Results of a post-hoc pooled analysis assessing factors associated with achieving target HbA1c <7.0% in people with type 2 diabetes treated with iGlarLixi from four clinical trials: NCT02058147, NCT02058160, NCT02787551 and EudraCT2017-003370-13 presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
    • 26 Jun 2023 Results (n=465) of a post-hoc pooled analysis assessing predictors of glycemic control in older people with type 2 diabetes treated with iGlarLixi from following clinical trials: NCT02058147, NCT02058160, NCT02787551 and EudraCT2017-003370-13 presented at the 83rd Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top